Anesiva’s Adlea gears up for Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anesiva will conduct two Phase III trials - one in knee replacement and one in bunionectomy surgeries - for its post-surgical pain candidate Adlea, the firm announces Oct. 10. A long-acting, non-opiate analgesic, Adlea is designed to provide pain relief for weeks to months following a single application. Both trials are expected to begin in the first half of 2008. Anesiva CEO John McLaughlin said the firm is also examining Adlea for other indications such as tendonitis and nerve damage...
You may also be interested in...
R&D In Brief
Cell Therapeutics completes enrollment in pixantrone Phase III trial; Elixir Pharmaceuticals type 2 drug mitiglinide enters final Phase III; Takeda stops development of cholesterol compound TAK-475 (lapaquistat); more R&D news, in brief
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.